⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) Key Ratios

Valuation, quality, health and growth. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.

Sources Company filings and market prices Filings and pricesRatios computed How we compute thisNot investment advice

8 figures withheld by our checks. Each blank figure names its reason.

41
VALUE
Fairly priced
in line with its peers
51
QUALITY
Decent
mid-pack profitability
22
HEALTH
Fragile
leverage needs watching
59
GROWTH
FCF only
growth rates not measurable; scored on FCF margin alone

A decent business at a fair price: value 41, quality 51, health 22, growth 59, each a percentile within Healthcare.

Values are the trailing twelve months where a company files quarterly statements and the figure passes our check against the filings, with balance-sheet ratios from the most recent quarter; otherwise, or where a sector's figure is still under review, the latest fiscal year. Piotroski and the five-year growth rates are fiscal years. Each row names its period.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own ten fiscal years (context, not scored)hover any metric for its formula
41st pctilein line with its peers
Earnings yield (EBIT/EV)EBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.0.8%6th pctileown record too shortTTM through Sep 30, 2026
P/E—Not meaningful: the company made a loss.
P/B1.885th pctileSep 30, 2026 balance sheet
P/FCF20.157th pctileTTM through Sep 30, 2026
EV / EBITDA36.215th pctileTTM through Sep 30, 2026 · as of close, Nov 16, 2026
22nd pctileleverage needs watching
Current ratio2.4441st pctileSep 30, 2026 balance sheet
Quick ratio(Cash, short-term investments and receivables) ÷ current liabilities, as the data vendor builds it. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.1.1325th pctileSep 30, 2026 balance sheet
Net debt / EBITDADebt less cash and all investments, including long-term stakes, over EBITDA, as the data vendor builds it8.5×5th pctileTTM through Sep 30, 2026
Interest coverage0.8×10th pctileown record too shortTTM through Sep 30, 2026
Debt / equity0.6729th pctileSep 30, 2026 balance sheet
51st pctilemid-pack profitability
ROIC0%48th pctileTTM through Sep 30, 2026
ROE0%49th pctileTTM through Sep 30, 2026
Gross margin76.0%68th pctileTTM through Sep 30, 2026
Net margin−0.5%41st pctileTTM through Sep 30, 2026
Income quality (CFO/NI)—Not meaningful: the company made a loss.
Piotroski F6 / 970th pctileown record too shortFiscal year to Sep 30, 2026
Altman Z1.926th pctileTTM through Sep 30, 2026
59th pctilegrowth rates not measurable; scored on FCF margin alone
Revenue CAGRThe yearly rate that compounds the earliest fiscal year's revenue into the latest one, over the true number of fiscal years between them (up to five). When the earliest year's revenue is zero or negative, the rate starts from the first later year with at least $10M of revenue, provided at least three years remain.—This growth figure starts in a period outside the history your plan includes.
EPS CAGR—This growth figure starts in a period outside the history your plan includes.
FCF margin15.3%72nd pctileTTM through Sep 30, 2026
the receipts behind the numbers above
Greenblatt earnings yield0.8%EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC0%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage0.8× EBIT ÷ interest expense, ranked within sector peers.
Percentiles computed nightly against 340 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value (the trailing twelve months or the latest fiscal year, as its row names) sits in the company's own ten fiscal-year record, shown for context and never blended into the score. Computed Nov 16, 2026 · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.